Please assess the completion status of the following clinical trial:

Trial Title: A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-myeloid malignancy~* At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless of schedule~* Eastern Cooperative Oncology Group performance status of 0-2~* Hemoglobin concentration of less than 11 g/dL within 24 hours before randomization~* Of legal age at the time written informed consent is obtained~Exclusion Criteria:~* Known history of seizure disorder~* Known primary hematologic disorder, which could cause anemia, other than a non-myeloid malignancy~* Unstable or uncontrolled disease/condition, related to or affecting cardiac function~* Clinically significant inflammatory disease~* Inadequate renal and/or liver function~* Known positive HIV test~* Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO~* Received more than 2 red blood cell (RBC) transfusions within 4 weeks before randomization or any RBC transfusion within 14 days before randomization, or any planned RBC transfusion between randomization and study day 1~* Received any erythropoietic therapy within 4 weeks before randomization or any planned erythropoietic therapy between randomization and study day 1~* Other investigational procedures~* Subject is currently enrolled in or less than 30 days since receipt of any investigational drug or device that is not approved by the applicable regulatory authority~* Pregnant or breast feeding~* Not using adequate contraceptive precautions~* Known sensitivity to any of the products to be administered during dosing~* Previously randomized in this study~* Concerns for subject's compliance with protocol procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darbepoetin alfa 500 mcg - Group A (Type: EXPERIMENTAL): None
- Darbepoetin alfa 2.25 mcg/kg - Group B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).